The patient was initially diagnosed with juvenile dermatomyositis (JDM) at age 10 years after a 6-month history of proximal muscle weakness, characteristic heliotrope rash, and Gottron’s papules. Diagnosis was established according to the 2017 EULAR/ACR classification criteria, which included elevated serum muscle enzymes, compatible electromyographic findings, and typical cutaneous features. Initial treatment consisted of oral prednisolone (2 mg/kg/day) and weekly methotrexate (15 mg/m²).

Despite partial improvement in muscle strength, she developed painful nodular lesions approximately 12 months after disease onset, consistent with calcinosis cutis. Over the next six months, the lesions coalesced and extended along fascial planes, resulting in diffuse, sheet-like calcification typical of calcinosis universalis.

The patient lives with her parents in a low-income suburban community. Household income is irregular, and medication supply interruptions occurred during follow-up. At presentation, her height and weight were below the 10th percentile for age (height = 132 cm; weight = 28 kg; BMI = 16.0 kg/m²), reflecting chronic disease and corticosteroid exposure. School attendance had declined due to mobility limitations and psychosocial distress related to the visible skin lesions.

The patient appeared thin and chronically ill but alert and cooperative. Multiple hard, immobile subcutaneous plaques were palpable over the thigh regions. Several smaller nodules were noted along the extensor surfaces of the knees, with overlying skin induration and mild ulceration in some areas. No muscle tenderness was elicited. The joints of the lower limbs exhibited reduced range of motion secondary to pain and soft-tissue stiffness.

Muscle strength was graded using Manual Muscle Testing-8 (MMT-8) with a composite score of 64/80, and her Childhood Myositis Assessment Scale (CMAS) score was 42/52, indicating mild-to-moderate residual weakness. Functional disability was moderate (Childhood Health Assessment Questionnaire [CHAQ]= 1.1).

Laboratory investigations revealed elevated serum creatine kinase (CK) = 486 U/L (reference 30–200 U/L) and aldolase = 9.5 U/L (reference 1.5–8.0 U/L). Erythrocyte sedimentation rate was 38 mm/hr. Serum calcium, phosphate, and parathyroid hormone levels were within normal limits, excluding metabolic causes of calcification. Renal and liver function tests were normal.

Testing for myositis-specific antibodies (anti-Mi-2, anti-TIF1-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\gamma$\end{document}γ, anti-MDA5, anti-NXP2) was unavailable locally, and this limitation is acknowledged. Antinuclear antibody (ANA) was positive (1:160, speckled pattern).

Plain radiographs of the lower limbs demonstrated extensive, symmetrical, sheet-like calcifications along subcutaneous and intramuscular planes, extending from the distal femur to the proximal tibia and fibula region . No periosteal reaction or bony involvement was observed.

Differentials considered included:

The patient was managed by a multidisciplinary team comprising rheumatology, dermatology, radiology, physiotherapy, and pediatric specialists. Oral methotrexate was continued, and oral prednisolone was tapered. Because of extensive calcinosis and persistent pain, intravenous immunoglobulin (IVIg) (2 g/kg monthly × 3 cycles) was initiated, followed by a calcium and phosphate-restricted diet, colchicine 0.5 mg daily, and intensive physiotherapy for joint mobilization. Over 6 months, the patient reported reduced joint pain and improved mobility, with no new calcific lesions noted.

Pain VAS decreased from 7/10 to 3/10, MMT-8 improved to 72/80, and CMAS increased to 47/52. No major adverse drug reactions were observed. The family was counseled about the chronic nature of the condition and the importance of adherence to therapy and physiotherapy.

The patient’s mother shared that before the diagnosis, she was deeply worried by her daughter’s persistent weakness and the appearance of hard swellings under the skin, which caused pain and made walking difficult. She expressed feelings of helplessness due to the family’s limited financial means and the long travel distance from their village to the hospital.

After several months of treatment and physiotherapy, she noticed significant improvement in her daughter’s ability to walk and participate in school activities. The family felt relieved that the pain and stiffness had lessened and that the child’s confidence was gradually returning. The mother emphasized that the hospital team’s continuous support and counseling helped them understand the importance of medication adherence and follow-up visits.

She also mentioned that seeing visible improvement despite their challenges gave her hope that other children in rural communities could recover if given timely and consistent medical care.

The patient remains under quarterly follow-up with periodic laboratory monitoring and annual radiographic evaluation. Multidisciplinary support, including psychological counseling and nutritional monitoring, continues as part of long-term management.

In the current case, calcinosis developed approximately one year after JDM diagnosis, consistent with timelines reported in recent case studies. Ferjani et al (2024) [¹] described a comparable pediatric case with extensive subcutaneous and fascial calcifications developing two years post-diagnosis, while Ostring et al. (2022) [¹³] reported a post–stem cell transplant patient who developed calcinosis universalis alongside hypercalcemia, underscoring the complexity of calcium metabolism in chronic inflammatory myopathies. Similarly, Jazayeri, Mehdizadeh, and Shahlaee (2012) [¹⁴] documented extensive calcinosis on skeletal radiographs, emphasizing that plain X-rays remain the most accessible diagnostic tool in resource-limited settings like Ghana.

Older reports have consistently highlighted that chronic disease activity, corticosteroid overuse, and vascular compromise promote calcium deposition [⁹,¹⁵]. The current case supports these findings, as the patient’s disease was only partially controlled during the initial treatment period due to irregular medication adherence - a reflection of socioeconomic barriers rather than therapeutic resistance.

The exact mechanism of calcinosis universalis remains unclear, but evidence points to a multifactorial process. Persistent inflammation and ischemia lead to tissue necrosis, releasing phosphate-rich vesicles that serve as nucleation sites for calcium salt precipitation [¹²]. Over time, these deposits coalesce into extensive plaques within muscles and subcutaneous tissue. Mitochondrial injury, local pH imbalance, and macrophage dysfunction also contribute to crystal formation [¹³]. This pathophysiology explains why aggressive early immunosuppression is essential to minimize chronic damage and calcinosis formation.

Plain radiography remains the cornerstone of diagnosis, revealing characteristic, sheet-like, or nodular calcifications along fascial planes and muscle groups [¹⁴]. Although CT and MRI provide superior spatial resolution, their use is often constrained in low- and middle-income settings due to cost and accessibility. In this case, radiographs were sufficient to delineate the full extent of calcification and monitor therapeutic response. These findings mirror those reported by [⁷], in which radiographs provided a reliable assessment of disease extent and response to therapy in an adult with calcinosis universalis.

The treatment of calcinosis universalis remains challenging, with no universally effective regimen. Reported interventions include immunosuppressive therapy, bisphosphonates, intravenous immunoglobulin (IVIg), diltiazem, colchicine, and surgical removal of localized deposits [¹⁶,¹⁷]. In our patient, the use of IVIg and colchicine was guided by reports from Touimy et al. (2013) [⁵] and Matsuoka et al. (1998) [¹⁶], who noted improvement in lesion progression and pain control. Terroso et al. (2013) [¹⁷] also observed partial resolution in adult dermatomyositis after combination therapy with corticosteroids and methotrexate. Conversely, Berger et al. (1987) [⁸] demonstrated benefit from low-dose warfarin, suggesting that modulation of calcium-binding proteins may reduce crystal formation; however, warfarin use in children remains controversial and requires careful monitoring.

Physiotherapy played a central role in this case, focusing on maintaining joint mobility, preventing contractures, and improving muscle strength. Similar functional recovery was reported by Boelch et al. (2015) [⁷], who found that rehabilitation significantly improved limb function after calcinosis reduction.

The prognosis of calcinosis universalis depends on the extent of soft-tissue involvement, therapeutic response, and access to multidisciplinary care. Persistent disease activity may lead to recurrent ulceration, infection, or joint contractures, as observed by Yun et al. (2006) and Cowley et al. (2022) [²,⁴]. Psychosocial effects - including stigma, anxiety, and school absenteeism - are frequently underreported but significantly impact quality of life. In our patient, parental support and counseling improved adherence and reduced distress, highlighting the importance of family-centered care.

This case underscores the need for early diagnosis, consistent immunosuppression, and multidisciplinary management in preventing severe calcinosis. In low-resource environments, where advanced imaging and antibody testing are often unavailable, careful clinical documentation, radiographic monitoring, and structured functional assessments remain crucial. Moreover, international collaborative registries could help establish evidence-based treatment protocols tailored to African pediatric populations.